First Hospital of Jilin University

Changchun 130021

0 studies enrolling now · 8 studies all time

What they study most

Atrial Fibrillation, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Heart Failure, Scleroderma, Systemic, Secondary Prevention, Stroke

Studies at this site

• EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved) — Completed
• EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced) — Completed
• GLORIA-AF Registry Program - Second and Third Phases — Completed
• A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer — Stopped early
• A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis — Completed
• Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS) — Completed
• LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment — Completed
• LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy — Completed